This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557.
Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158–1164.
Delima M, Ghaddar H, Pierce S, Estey E . Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 1996; 93: 89–95.
Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649.
Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006; 20: 1319–1321.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mesa, R., Tefferi, A., Li, CY. et al. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia 20, 2063–2064 (2006). https://doi.org/10.1038/sj.leu.2404398
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404398
This article is cited by
-
Thalidomide treatment in a myelofibrosis patient with leukemia transformation
International Journal of Hematology (2014)
-
CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT
Bone Marrow Transplantation (2010)
-
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Leukemia (2008)
-
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
Leukemia (2008)
-
Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
Cancer Immunology, Immunotherapy (2008)